Iovance Biotherapeutics Inc (NASDAQ:IOVA) shares reached a new 52-week high on Thursday . The company traded as high as $18.68 and last traded at $17.75, with a volume of 877200 shares. The stock had previously closed at $17.75.
A number of research analysts recently weighed in on IOVA shares. B. Riley boosted their target price on Iovance Biotherapeutics from $17.50 to $18.00 and gave the stock a “buy” rating in a report on Wednesday, November 1st. Oppenheimer set a $13.00 target price on Iovance Biotherapeutics and gave the stock a “buy” rating in a report on Tuesday, October 31st. HC Wainwright set a $16.00 target price on Iovance Biotherapeutics and gave the stock a “buy” rating in a report on Monday, October 30th. Jefferies Group reissued a “buy” rating on shares of Iovance Biotherapeutics in a report on Sunday, October 29th. Finally, FBR & Co reissued a “buy” rating and set a $17.50 target price on shares of Iovance Biotherapeutics in a report on Wednesday, October 25th. Two equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. Iovance Biotherapeutics presently has an average rating of “Buy” and a consensus target price of $18.75.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in IOVA. Parametric Portfolio Associates LLC bought a new stake in Iovance Biotherapeutics in the 2nd quarter valued at $125,000. Dynamic Technology Lab Private Ltd bought a new stake in Iovance Biotherapeutics in the 3rd quarter valued at $133,000. Ellington Management Group LLC boosted its stake in Iovance Biotherapeutics by 39.1% in the 4th quarter. Ellington Management Group LLC now owns 19,200 shares of the biotechnology company’s stock valued at $154,000 after purchasing an additional 5,400 shares during the period. Teacher Retirement System of Texas bought a new stake in Iovance Biotherapeutics in the 4th quarter valued at $154,000. Finally, Jane Street Group LLC bought a new stake in Iovance Biotherapeutics in the 3rd quarter valued at $164,000. Institutional investors and hedge funds own 65.08% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Iovance Biotherapeutics (IOVA) Hits New 1-Year High at $18.68” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://www.dispatchtribunal.com/2018/02/22/iovance-biotherapeutics-iova-hits-new-1-year-high-at-18-68.html.
Iovance Biotherapeutics Company Profile
Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.